CJC-1295 (No DAC) 2mg — Vial Spec, Reconstitution Math & COA

Overview of the CJC-1295 (No DAC) 2mg Vial Specification

In laboratory settings, the 2mg vial size of CJC-1295 (No DAC) serves as an optimal unit mass for bench-scale experimental workflows. This quantity allows researchers to perform serial dilution protocols and multi-well cell culture assays without subjecting large bulk quantities of peptide to repeated freeze-thaw cycles. Each 2mg glass vial contains a lyophilized cake of high-purity synthetic peptide alongside residual counter-ions resulting from trifluoroacetic acid (TFA) exchange, sealed under inert gas to maintain structural stability.

Principal investigators and laboratory technicians typically select the 2mg presentation when running targeted short-term assays or micro-dosing protocols in animal models. PX1 Research provides high-purity analytical standards suitable for controlled laboratory evaluation. Researchers seeking access to full inventory listings can explore our comprehensive catalog of research peptides to compare formats, structural variants, and volume configurations.

Chemical Identity, Receptor Binding, and Preclinical Mechanism

CJC-1295 (No DAC) is a 29-amino acid synthetic peptide representing a modified variant of human Growth Hormone-Releasing Hormone (GHRH 1-29). The primary sequence features specific alanine-to-D-alanine and glutamine-to-glutamic acid substitutions at positions 2, 8, 15, and 27. These specific side-chain modifications enhance structural resistance against enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV) without altering the binding affinity for the GHRH receptor (GHRHR) located on pituitary somatotrophes.

Unlike CJC-1295 with Drug Affinity Complex (DAC), which incorporates a reactive maleimide linker that covalently binds serum albumin, CJC-1295 (No DAC) retains a physiological half-life measured in minutes rather than days. In animal models, this short half-life enables researchers to simulate normal physiological pulsatile growth hormone secretion patterns. Preclinical studies suggest that GHRH analogs of this class stimulate adenylate cyclase via G-protein coupled receptors, raising intracellular cAMP and downstream insulin-like growth factor 1 (IGF-1) expression, which plays a pivotal role in tissue repair research and cellular metabolism investigations.

Reconstitution Math and Concentration Calculations for 2mg Vials

Accurate reconstitution is critical to maintaining quantitative precision in laboratory assays. Reconstituting a 2mg (2000 mcg) lyophilized cake of CJC-1295 (No DAC) with varying volumes of bacteriostatic water or sterile standard diluent yields distinct final working concentrations. To achieve exact target concentrations, investigators can utilize the following reference math:

1. Reconstitution with 1.0 mL Diluent: Yields a concentration of 2.0 mg/mL (2000 mcg/mL). Every 0.05 mL (50 microliters) contains exactly 100 mcg of active peptide compound. This concentrated solution is advantageous for high-density cellular assays where minimal liquid volume displacement is required.

2. Reconstitution with 2.0 mL Diluent: Yields a concentration of 1.0 mg/mL (1000 mcg/mL). Every 0.05 mL contains 50 mcg of compound. This 1:1 ratio simplifies mathematical conversion during micro-pipetting operations across multi-well plates or animal dosing regimens.

3. Reconstitution with 3.0 mL Diluent: Yields a concentration of 0.667 mg/mL (666.7 mcg/mL). Every 0.05 mL delivers approximately 33.3 mcg of peptide. Lower concentration working stocks are useful when running micro-assays requiring low mass inputs per well.

For complex dilution protocols or automated pipetting workflows, researchers can verify precision calculations using our integrated laboratory reconstitution calculator.

Laboratory Handling, Aliquoting, and Storage Stability

Lyophilized CJC-1295 (No DAC) 2mg vials should be stored at -20°C or -80°C upon receipt to maintain long-term stability for up to 24 months. Exposure to room temperature during transit does not degrade the dry cake due to state-of-the-art lyophilization matrices, but long-term exposure to ambient heat and moisture will degrade peptide bonds via hydrolysis.

Once reconstituted with bacteriostatic water containing 0.9% benzyl alcohol, working solutions should be refrigerated at 2°C to 8°C and utilized within 21 to 28 days. To prevent chemical degradation caused by repeated freeze-thaw events, liquid stock solutions should be divided into single-use micro-aliquots using sterile polypropylene tubes and maintained at -80°C. Light exposure should be minimized, as tryptophan and tyrosine residues within peptide sequences can undergo photo-oxidation.

Quality Assurance: Certificate of Analysis, HPLC, and Endotoxin Testing

Every production lot of CJC-1295 (No DAC) 2mg undergoes rigorous analytical validation prior to release. PX1 Research mandates third-party high-performance liquid chromatography (HPLC) and mass spectrometry (MS) testing performed in ISO 17025 accredited testing facilities. HPLC analysis confirms chemical purity exceeding 98.0%, ensuring that truncated synthesis fragments and counter-ion impurities are minimized.

Mass spectrometry confirms exact molecular mass matching the theoretical molecular weight of 3367.9 g/mol. Additionally, endotoxin testing is conducted via Chromogenic LAL assay protocols to ensure levels remain below strictly defined laboratory limits (<0.01 EU/mg), avoiding false-positive inflammatory responses in cell culture models. Researchers can review batch-specific documentation directly via our verified COA portal.

Comparative Analysis: CJC-1295 (No DAC) vs. Related Somatotropic Peptides

When designing preclinical GH axis stimulation experiments, researchers often evaluate CJC-1295 (No DAC) alongside complementary peptides in the same receptor class. Selecting the appropriate secretagogue depends on whether the experimental model requires pure GHRH receptor signaling or synergistic GHRP activation.

For instance, Ipamorelin acts selectively as a Growth Hormone Secretagogue Receptor (GHSR-1a) agonist, triggering GH release via pathways independent of GHRHR. When researchers aim to evaluate maximal secretagogue response in vitro, co-administration of CJC-1295 (No DAC) with Ipamorelin often demonstrates a synergistic secretagogue effect greater than either compound administered alone. Conversely, GHRH analogs such as Tesamorelin feature structural variations tailored toward lipid metabolism models, while legacy ghrelin mimetics like GHRP-2 stimulate alternative signaling pathways that may also elevate cortisol and prolactin levels. Comparing these distinct secretagogue classes allows laboratories to isolate specific endocrine mechanisms.

Preclinical Applications in Tissue Repair and Cell Culture Research

Preclinical literature demonstrates that GHRH analogs like CJC-1295 (No DAC) are valuable tools in tissue repair research. In rodent models of musculoskeletal injury, sustained downstream IGF-1 expression driven by GHRH receptor activation has been observed to accelerate satellite cell proliferation and collagen synthesis within connective tissues.

In vitro assays using primary chondrocytes and tenocytes indicate that GHRH activation regulates matrix metalloproteinase expression, helping maintain structural integrity during induced metabolic stress. Researchers exploring myogenesis, bone remodeling, and cellular regeneration utilize CJC-1295 (No DAC) 2mg to model localized growth factor pathways without introducing long-acting systemic accumulation.

Sourcing Strategy: Selecting 2mg Vials vs. Bulk Research Quantities

Choosing the 2mg vial specification is advantageous for laboratories performing exploratory screening assays, assay standardization trials, or experiments requiring fresh reconstituted stock every few weeks. Because reconstituted peptides gradually degrade over prolonged liquid storage, smaller 2mg units prevent unnecessary waste of analytical-grade material.

For larger-scale preclinical trials or institutional research departments executing longitudinal animal studies, multi-vial procurement or bulk sizes may offer improved operational efficiency. You can review unit parameters for our primary listing on the CJC-1295 (No DAC) product page. Institutional procurement teams requiring custom fill volumes or dedicated lot reservation can coordinate via our dedicated wholesale program.

Standard Operating Protocol Checklist for Lab Reconstitution

To maximize experimental reproducibility when preparing CJC-1295 (No DAC) 2mg for laboratory assays, adhere to the following standard operating procedure:

1. Environmental Preparation: Perform all reconstitution steps within a certified Class II Type A2 Laminar Flow Biosafety Cabinet to maintain sterility. 2. Vial Sanitization: Decontaminate the rubber septum of the peptide vial and diluent vial using 70% isopropyl alcohol wipes prior to needle insertion. 3. Diluent Addition: Using a sterile low-dead-volume syringe, aspirate the precise volume (e.g., 2.0 mL) of diluent and slowly inject it down the glass wall of the vial to minimize shear force on the peptide matrix. 4. Dissolution: Allow the vial to sit upright for 5 minutes. Gentle swirling may be applied; do not agitate or vortex vigorously. 5. Verification: Inspect the solution visually under bright lighting. The final solution must appear completely clear, colorless, and free of visible particulate matter prior to use.